Evidence map›Paper›PMID 42325473›Full record

ArticleLancet regional health. Americas2026

Person-centered choice and mHealth support for same-day delivery of long-acting injectable cabotegravir (ImPrEP CAB Brasil): a prospective, open-label, multicenter, quasi-experimental implementation study.

Thiago Silva Torres, Brenda Hoagland, Carolina Coutinho, Mayara Secco Torres Silva, Ronaldo Ismério Moreira, Iuri Costa Leite, Marcelo Cunha, Emilia M Jalil, Sandra Wagner Cardoso, Roberta Trefiglio and 17 more

Registry-linked trialAbstract read
In one paragraph

Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05515770 (An Implementation Study of Long-acting Injectable Cabotegravir), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05515770 phase3recruitingnot on this map

An Implementation Study of Long-acting Injectable Cabotegravir (CAB-LA) for HIV Pre-Exposure Prophylaxis (PrEP) Among Young MSM, Non-binary and Transgender Persons (The ImPrEP CAB Study)

TypeinterventionalSponsorEvandro Chagas National Institute of Infectious DiseaseRan2022 to 2026Enrolled1,200ConditionsHIV InfectionsArmsCabotegravir Injection
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Thiago Silva TorresFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Brenda HoaglandFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Carolina CoutinhoFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Mayara Secco Torres SilvaFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Ronaldo Ismério MoreiraFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Iuri Costa LeiteFundacão Oswaldo Cruz, Escola Nacional de Saúde Pública (ENSP-Fiocruz), Rio de Janeiro, Brazil.
Marcelo CunhaFundacão Oswaldo Cruz, Escola Nacional de Saúde Pública (ENSP-Fiocruz), Rio de Janeiro, Brazil.
Emilia M JalilFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Sandra Wagner CardosoFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Roberta TrefiglioFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Alessandro FariasCentro Especializado em Diagnóstico, Assistência e Pesquisa -CEDAP, Salvador, Brazil.
Maria Paula G MourãoFundação de Medicina Tropical Heitor Vieira Dourado, Manaus, Brazil.
José Valdez MadrugaCentro de Referência e Treinamento em DST/Aids - CRT, São Paulo, Brazil.
Josué N de LimaCentro de Referência em DST/Aids, Campinas, Brazil.
Ronaldo ZontaCTA/Policlínica Centro, Florianópolis, Brazil.
Gabrielle O'MalleyDepartment of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, WA, United States.
Julio MoreiraGrupo Arco-Íris de Cidadania LGBT, Rio de Janeiro, Brazil.
Keila SimpsonAssociação Nacional de Travestis e Transexuais (ANTRA), Salvador, Bahia, Brazil.
Heather A PinesSchool of Public Health, San Diego State University, San Diego, CA, USA.
Alex R RinehartViiV Healthcare, London, England.
Nanlesta PilgrimViiV Healthcare, London, England.
Paula M LuzFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Marcos BenedettiFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Maria Cristina PimentaFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Valdilea Gonçalves VelosoFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
Beatriz GrinsztejnFundacão Oswaldo Cruz, Instituto Nacional de Infectologia Evandro Chagas (INI-Fiocruz), Rio de Janeiro, Brazil.
ImPrEP CAB Brasil Study Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Long-acting injectable cabotegravir (CAB-LA) offers a promising alternative to daily oral PrEP. However, studies evaluating PrEP choice and mHealth tools designed to support informed PrEP decision-making in real-world public health settings are scarce. We evaluated PrEP choice and the impact of an mHealth tool. Methods: ImPrEP CAB Brasil is a prospective, multicenter, quasi-experimental, implementation study conducted in six public health services in Brazil. Eligible participants were PrEP-naïve cisgender men, transgender and non-binary persons who have sex with men, aged 18-30 years, who tested negative for HIV. Participants were offered a person-centered model that provided a choice between same-day delivery of CAB-LA and oral PrEP. To support informed decision-making, participants were allocated (1:1) to standard-of-care counseling (SOC) or mHealth tool + SOC (first half enrolled in each site received SOC and the remaining received mHealth + SOC). Modified Poisson regression models estimated the effects of exposures of interest, study arm and Decisional Conflict Scale (DCS), on CAB-LA choice. Registered at ClinicalTrials.gov (NCT05515770). Findings: From October-2023 to October-2024, 1447 participants were enrolled: 738 (51.0%) to SOC arm and 709 (49.0%) to mHealth + SOC arm. Overall, 1201 (82.9%) participants chose CAB-LA. Participants allocated to mHealth + SOC arm were more likely to choose CAB-LA compared to SOC (PR: 1.15; 95% CI 1.10-1.21). Higher DCS scores were associated with a lower prevalence ratio of choosing CAB-LA (PR: 0.99; 95% CI 0.98-0.99). A total of 678 (95.7%) participants were satisfied with the mHealth tool and 659 (92.9%) found it supported PrEP decision. Interpretation: We found a strong preference for CAB-LA among young sexual and gender diverse populations. The mHealth intervention was highly acceptable and supported informed-decision, indicating its utility as a scalable strategy in real-world settings. These findings are crucial for guiding the equitable scale-up of CAB-LA and advancing HIV prevention in Latin America. Funding: Unitaid, WHO, Brazilian Ministry of Health.

Indexed as

Digital healthLatin AmericaLong-acting PrEPMen who have sex with menSexual and gender minoritiesTransgender

Identifiers

PMID42325473
PMCPMC13279416

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.